Author's response to reviews

Title: DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

Authors:

Javier Martinez-Useros (javier.museros@fjd.es)
Maria Rodriguez (maria.rremirez@idcsalud.es)
Aurea Borrero (aurea.borrero@idcsalud.es)
Irene Moreno (irene.mcandilejo@idcsalud.es)
Arancha Cebrian (arancha.ceblrian@idcsalud.es)
Teresa Gomez del Pulgar (mteresa.gpulgar@idcsalud.es)
Laura del Puerto (lpuerto@idcsalud.es)
Ricardo Vega-Bravo (ricardovegabravo@yahoo.es)
Alberto Puime (albertorrente@hotmail.com)
Nuria Perez (nperez@idcsalud.es)
Sandra Sazo (szazo@idcsalud.es)
Clara Senin (cinse@hotmail.com)
Maria J Fernandez-Aceñero (mgg10167@gmail.com)
Maria S Soengas (msoengas@cnio.es)
Federico Rojo (frojo@idcsalud.es)
Jesus Garcia-Foncillas (jgfoncillas@gmail.com)

Version: 4 Date: 10 December 2014

Author's response to reviews: see over
Dear Editor,

Thank you very much for your letter and comments on our manuscript (1245482012146008).

We do appreciate the suggestions for the improvement of the manuscript; all comments have been taken into consideration and properly answered following each query. We hope that after this revision it will be suitable for reevaluation and publication in BMC Cancer. The manuscript has been carefully reviewed following the “Guidelines for Submission of Manuscripts”.

Thanks to consider our work potentially acceptable for publication in BMC Cancer. I am looking forward to hearing from you soon.

Sincerely,

Dr. Jesús García-Foncillas
Responses to comments of Editor

After revising the manuscript, we agree with Editor that there are some points in the manuscript that needed to be clarified.

Editor’s Request:

1. Please clarify the full name of the institutional scientific and ethical committee which approved your study, in addition please include an approval reference number.

According to Editor request, we have complemented the Patient’s information of the Methods Section (page 5, line 20-23) with the full name of the institutional scientific and ethical committee and the reference number. In addition, we have added the reference number of the BioBank of the Fundación Jimenez Diaz-Universidad Autonoma de Madrid.

2. Please clarify the author contribution of M. J. Fernandez-Aceñero, in your author contributions section.

Effectively, as the Editor has commented, we have not added the contribution of M. J. Fernandez-Aceñero in the properly section. We appreciate this suggestion and we have modified the “Contributions Section” including M. J. F.-A for her contribution to analytic tools (page 15, line 16).

We hope that these additional explanations and changes have improved the manuscript and now it may be suitable for publication in BMC Cancer.